Short-Term Atorvastatin Treatment to Prevent Atrial Fibrillation After Lung Surgery in Adults 60 and Older

What this Trial Is About

Researchers are evaluating whether short-term treatment with atorvastatin can prevent new abnormal rapid heart rhythms, including atrial fibrillation, after lung surgery in adults aged 60 years or older who are scheduled for lung segment or lobe removal. The study also aims to assess the safety of this treatment around the time of surgery by monitoring medical problems and changes in liver, kidney, or muscle-related lab tests. Participants will be randomly assigned to receive either atorvastatin or a matching placebo. Those assigned to atorvastatin will take 40 mg daily, starting 2 to 7 days before surgery and continuing until 72 hours after surgery. Participants already on moderate-intensity statins will receive a standardized regimen to avoid stopping their usual treatment. Heart monitoring will be done continuously for 72 hours after surgery to detect abnormal rhythms. During the hospital stay and for 30 days after surgery, researchers will collect routine clinical information, blood tests, and safety data. The main outcome is the number of participants who develop new atrial fibrillation or related rapid heart rhythms within 72 hours after surgery. The study includes close monitoring of safety and follow-up assessments to evaluate treatment effects and potential side effects.

Perioperative Statins to Prevent AFib After Lung Surgery